Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Asia-Pacific Respiratory Syncytial Virus Market: Epidemiology Forecast to 2028 - ResearchAndMarkets.com

November 18, 2019

DUBLIN--(BUSINESS WIRE)--Nov 18, 2019--

The “Respiratory Syncytial Virus: Epidemiology Forecast in Asia-Pacific Markets to 2028” report has been added to ResearchAndMarkets.com’s offering.

Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. In healthy individuals RSV usually self-resolves within a week or two without need for significant therapeutic intervention. In preterm and very young infants, the elderly, or those with otherwise compromised immune systems, however, RSV can cause severe illness or death.

It has been estimated that up to 30 million episodes of RSV-related lower respiratory infection occur annually worldwide, with the majority of those cases occurring in low-income countries. RSV is also considered to be the leading cause of bronchiolitis and pneumonia in children less than one year old and one of the leading causes of respiratory disease in older adults. Currently RSV has neither a known cure nor a vaccine; however, preventive measures can be taken to help mitigate the spread of the disease

The author’s epidemiologists provide a well-rounded, evidence-based analysis and forecast for the hospitalized and prophylactic populations for RSV in this report. This analysis covered all at-risk groups that are recommended for RSV prophylactic treatment. Each population, including the hospitalized population, is also segmented by ages and by sex, thereby providing a granular visualization of the RSV prophylactic and hospitalized markets in the 5GM.


Reasons to Buy

The RSV Epidemiology series will allow you to -

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Respiratory Syncytial Virus: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources Used and Not Used

3.4.2 Forecast Assumptions and Methods

3.5 Epidemiological Forecast for RSV Hospitalized Population (2018-2028)

3.5.1 Number of Hospitalized Adults with Positive RSV Test

3.5.2 Number of Children Hospitalized for Confirmed RSV

3.6 Epidemiological Forecast for RSV Prophylactic Population (2018-2028)

3.6.1 Number of Preterm Births by Gestational Age

3.6.2 Preterm Infants with CLD

3.6.3 Number of Live Births with Hemodynamically Significant Heart Disease

3.6.4 Diagnosed Prevalent Cases of DMD

3.6.5 Number of Diagnosed Prevalent Cases of SMA

3.6.6 Number of Third Trimester Pregnant Women

3.6.7 Number of Adults Living in Nursing Homes/Long-Term Care Institutions

3.7 Discussion

3.7.1 Epidemiological Forecast Insight

3.7.2 Limitations of Analysis

3.7.3 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About the Author

4.4 Contact Us

4.5 Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/ekr72x

View source version on businesswire.com:https://www.businesswire.com/news/home/20191118005736/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/18/2019 01:31 PM/DISC: 11/18/2019 01:31 PM